A member of the tumor necrosis factor (TNF) superfamily, human TNFSF14 (hTNFSF14)/HVEM-L (herpes virus entry mediator ligand) was isolated as a cellular ligand for HVEM/TR2 and human lymphotoxin β receptor (LTβR). TNFSF14 induces apoptosis and suppresses tumor formation. We have isolated a cDNA clone for a mouse homologue of hTNFSF14 by signal sequence trap (SST) screening which we recently developed. The deduced amino acid sequence of the mouse TNFSF14 (mTNFSF14) cDNA comprised 239 amino acid residues and was 77% identical to the hTNFSF14 protein. In Northern blot analysis, 2.1 kb and 4.2kb mTNFSF14 transcripts were detected in spleen and lung, and in heart, respectively. Fluorescence in situ hybridization analysis localized the mTNFSF14 gene Tnfsf14 to chromosome 17 which is tightly linked with Tnf,Lta, and Ltb.   

1.
Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP, Hession C, O’Brine-Greco B, Foley SF, Ware CF: Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with Lymphotoxin on the cell surface. Cell 72:847–856 (1993).
2.
Disteche CM, Brannan CI, Larsen A, Adler DA, Schorderet DF, Gearing D, Copeland NG, Jenkins NA, Park LS: The human pseudoautosomal GM-CSF receptor α subunit gene is autosomal in mouse. Nature Genet 1:333–336 (1992).
3.
Hirai M, Suto Y, Kanoh M: A method for simultaneous detection of fluorescent G-bands and in situ hybridization signals. Cytogenet Cell Genet 66:149–151 (1994).
4.
Kojima T, Kitamura T: A signal sequence trap based on a constitutively active cytokine receptor. Nature Biotech 17:487–490 (1999).
5.
Lawton P, Nelson J, Tizard R, Browning JL: Characterization of the mouse Lymphotoxin-β gene. J Immunol 154:239–246 (1995).
6.
Matsuda Y, Harada Y, Natuume-Sakai S, Lee K, Shiomi T, Chapman VM: Localization of the mouse complement factor H gene (Cfh) by FISH analysis and replication R-banding. Cytogenet Cell Genet 61:282–285 (1992).
7.
Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu G, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF: LIGHT, a new member of the TNF superfamily, and Lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8:21–30 (1998).
8.
Milatovich A, Kitamura T, Miyajima A, Francke U: Gene for the α-subunit of the human interleukin-3 receptor (IL3RA) localized to the X-Y pseudoautosomal region. Am J hum Genet 53:1146–1153 (1993).
9.
Miyajima I, Levitt L, Hara T, Bedell MA, Copeland NG, Jenkins NA, Miyajima A: Chromosomal localization, genomic structure and promoter function. Blood 85:1246–1253 (1995).
10.
Onishi M, Mui ALF, Morikawa, Cho YL, Kinoshita S, Nolan GP, Gorman DM, Miyajima A, Kitamura T: Identification of an oncogenic form of the thrombopoietin receptor Mpl using retrovirus-mediated gene transfer. Blood 88:1399–1406 (1996).
11.
Rappold G, Willson TA, Henke A, Gough NM: Arrangement and localization of the human GM-CSF receptor α chain gene CSF2RA within the X-Y pseudoautosomal region. Genomics 14:455–461 (1992).
12.
Rigas B, Welcher AA, Ward DC, Weissman SM: Rapid plasmid library screening using RecA-coated biotinylated probes. Proc natl Acad Sci, USA 83:9591–9595 (1986).
13.
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J biol Chem 274:13733–13736 (1999).
14.
Zhai Y, Guo R, Hsu T, Yu G, Ni J, Kwon BS, Jiang G, Lu J, Tan J, Ugustus M, Carter K, Rojas L, Zhu F, Lincoln C, Endress G, Xing L, Wang S, Oh K, Gentz R, Ruben S, Lippman ME, Hsieh S, Yang D: LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 102:1142–1151 (1998).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.